Following on from information provided to NICE by the company in February 2021, the appraisal of AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1428 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Following on from information provided to NICE by the company in February 2021, the appraisal of AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2021, the appraisal of AT406 for neoadjuvant treatment of epithelial ovarian cancer [ID1428] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 12 February 2021 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of AT406 for neoadjuvant treatment of epithelial ovarian cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 12 February 2021 | Suspended. Topic is suspended |
For further information on our processes and methods, please see our CHTE processes and methods manual